Pioneering a new treatment
paradigm in inflammatory
driven airway disease
Areteia Therapeutics is a clinical stage biotechnology company committed to improving the lives of respiratory patients by putting them in better control of their disease with the first potential oral drug for eosinophilic asthma.
Asthma is a major global healthcare problem.
Worldwide:
- 262 million people affected
- 500 thousand deaths per year
In the U.S.:
- ~6 million doctor office visits annually
- 1.6 million emergency department visits annually
More than half of asthma patients have eosinophilic asthma, a type of asthma that is often severe and hard to treat.
262m
people worldwide are
affected by asthma
Despite the recent approvals of new injectable biologic medicines for eosinophilic asthma, profound unmet need and burden of illness remain.
While there are an estimated 3 million U.S, and E.U. patients living with severe eosinophilic asthma, fewer than 1 in 10 of these patients are actually receiving biologic therapy today.
Half of severe asthma patients in the U.S. are hospitalized at least once annually, driving an estimated $21 billion in direct healthcare system costs.
~3m
people have severe
eosinophilic asthma
in the U.S. and E.U.
Our mission is to transform the challenging patient journey in eosinophilic asthma.
Our Advanced Candidate
Dexpramipexole
Our lead investigational candidate is dexpramipexole, a first-in-class oral drug that inhibits the maturation of eosinophils before they can cause damage.
Dexpramipexole’s tolerability and eosinophil-lowering efficacy have been assessed in more than 1,500 patients in multiple indications, opening the potential for the first oral drug ever approved for eosinophilic asthma.
